Live Breaking News & Updates on Prothena Corporation

Stay updated with breaking news from Prothena corporation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Q2 2024 Earnings Forecast for Prothena Co. plc Issued By Zacks Research (NASDAQ:PRTA)

Prothena Co. plc (NASDAQ:PRTA – Free Report) – Analysts at Zacks Research upped their Q2 2024 earnings per share (EPS) estimates for Prothena in a research report issued on Monday, May 27th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn ($1.22) per share for the quarter, up from their previous […] ....

United States , Zacks Research , Royal Bank , Financial Services Group Inc , Cantor Fitzgerald , Analysts At Zacks Research , Capital Management , Allspring Global Investments Holdings , Prothena Corporation , Prothena Co , Headlands Technologies , Prothena Company Profile , China Universal Asset Management Co , Free Report , Get Free Report , Services Group , Global Investments Holdings , China Universal Asset Management , Universal Asset Management , Prothena Daily ,

Prothena Co. plc (NASDAQ:PRTA) Receives $67.00 Average Price Target from Analysts

Shares of Prothena Co. plc (NASDAQ:PRTA – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month […] ....

United States , Cantor Fitzgerald , E Fund Management Co , Fund Management Co , Qube Research Technologies Ltd , Prothena Co , Sg Americas Securities , Prothena Corporation , Get Free Report , Technologies Ltd , Fund Management , Get Free , Prothena Daily ,

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target

Prothena will. ....

Richard Hargreaves , Prothena Corporation , Bristol Myers Squibb , Exchange Commission , Company On Twitter Prothenacorp , Drug Administration , Gene Kinney , Chief Executive Officer , Senior Vice President , Neuroscience Thematic Research , Quarterly Report ,

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will ....

Richard Hargreaves , Michael Bachner , Mark Johnson , Corporate Communications , Bristol Myers Squibb , Company On Twitter Prothenacorp , Drug Administration , Exchange Commission , Prothena Corporation , Gene Kinney , Chief Executive Officer , Senior Vice President , Neuroscience Thematic Research , Quarterly Report , Senior Director , Vice President , Investor Relations , Ihr Portfolio ,

Prothena Co. plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Prothena Co. plc (NASDAQ:PRTA – Get Free Report) have been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average […] ....

United States , E Fund Management Co , Fund Management Co , Cantor Fitzgerald , Sg Americas Securities , Prothena Corporation , Qube Research Technologies Ltd , Prothena Co , Prothena Company Profile , Get Free Report , Trading Down , Technologies Ltd , Fund Management , Get Free , Prothena Daily ,